SCHEMBL30796629

SCHEMBL30796629

CC(C)(C)OC(=O)N1CCN(c2ccnc(-c3cc(-c4ccccc4O)nnc3N)c2)CC1

nearest known ligand 0.72

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 11/20 0.72
▸ SMARCA4 P51532 11/20 0.72
▸ PBRM1 Q86U86 9/20 0.72
▸ PDK2 Q15119 1/20 0.46
▸ NR1I2 O75469 3/20 0.44
▸ BRD4 O60885 2/20 0.44
▸ PIK3CA P42336 1/20 0.44
▸ PTPN11 Q06124 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ CHRNA7 P36544 1/20 0.42
▸ MAP4K4 O95819 1/20 0.41
▸ KIT P10721 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27461170 1.00 SMARCA2 (0.72) SMARCA2SMARCA4PBRM1PDK2NR1I2
SCHEMBL27461283 0.89 SMARCA2 (0.57) SMARCA2SMARCA4PBRM1PDK2PIK3CA
SCHEMBL30796360 0.88 SMARCA2 (0.58) SMARCA2SMARCA4PBRM1PDK2PIK3CA
SCHEMBL30796928 0.86 SMARCA2 (0.54) SMARCA2SMARCA4PBRM1PDK2PIK3CA
SCHEMBL30796853 0.86 SMARCA2 (0.52) SMARCA2SMARCA4PBRM1PDK2PIK3CA
SCHEMBL27461169 0.86 SMARCA2 (0.52) SMARCA2SMARCA4PBRM1PDK2PIK3CA
SCHEMBL25347040 0.86 SMARCA2 (0.76) SMARCA2SMARCA4PBRM1PDK2NR1I2
SCHEMBL30520252 0.86 SMARCA2 (0.76) SMARCA2SMARCA4PBRM1PDK2NR1I2
SCHEMBL30667399 0.84 PBRM1 (1.00) SMARCA2SMARCA4PBRM1NR1I2BRD4
SCHEMBL18038763 0.84 PBRM1 (1.00) SMARCA2SMARCA4PBRM1NR1I2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539849-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
Send feedback